NI201500090A - Composiciones de nanopartículas de albúmina y paclitaxel - Google Patents
Composiciones de nanopartículas de albúmina y paclitaxelInfo
- Publication number
- NI201500090A NI201500090A NI201500090A NI201500090A NI201500090A NI 201500090 A NI201500090 A NI 201500090A NI 201500090 A NI201500090 A NI 201500090A NI 201500090 A NI201500090 A NI 201500090A NI 201500090 A NI201500090 A NI 201500090A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compositions
- albumin
- paclitaxel nanoparticles
- paclitaxel
- nanoparticles
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 3
- 108010088751 Albumins Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229930012538 Paclitaxel Natural products 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 229960001592 paclitaxel Drugs 0.000 title abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747123P | 2012-12-28 | 2012-12-28 | |
| US13/794,705 US20140186447A1 (en) | 2012-12-28 | 2013-03-11 | Nanoparticle compositions of albumin and paclitaxel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201500090A true NI201500090A (es) | 2015-12-22 |
Family
ID=51017455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201500090A NI201500090A (es) | 2012-12-28 | 2015-06-26 | Composiciones de nanopartículas de albúmina y paclitaxel |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140186447A1 (OSRAM) |
| EP (1) | EP2938340A4 (OSRAM) |
| JP (2) | JP2016504362A (OSRAM) |
| KR (1) | KR20150100903A (OSRAM) |
| CN (1) | CN105007912A (OSRAM) |
| AU (1) | AU2013370955B2 (OSRAM) |
| BR (1) | BR112015015319A2 (OSRAM) |
| CA (1) | CA2896288A1 (OSRAM) |
| CR (1) | CR20150386A (OSRAM) |
| HK (1) | HK1216611A1 (OSRAM) |
| IL (1) | IL239593A0 (OSRAM) |
| MX (1) | MX2015008361A (OSRAM) |
| NI (1) | NI201500090A (OSRAM) |
| NZ (1) | NZ630912A (OSRAM) |
| PH (1) | PH12015501486B1 (OSRAM) |
| RU (1) | RU2663687C2 (OSRAM) |
| SG (1) | SG11201505111TA (OSRAM) |
| WO (1) | WO2014105644A1 (OSRAM) |
| ZA (1) | ZA201504762B (OSRAM) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| BR112015029853A2 (pt) | 2013-05-30 | 2017-07-25 | Nanobiotix | uso de uma composição farmacêutica |
| CA2950926A1 (en) | 2014-06-13 | 2015-12-17 | Mayo Foundation For Medical Education And Research | Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| CN104224750A (zh) * | 2014-09-17 | 2014-12-24 | 四川大学 | 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| PT3229776T (pt) | 2014-11-25 | 2023-08-17 | Curadigm Sas | Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações |
| JP6789960B2 (ja) | 2014-11-25 | 2020-11-25 | キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ | 医薬組成物、その調製及び使用 |
| LT3223796T (lt) | 2014-11-25 | 2021-10-25 | Curadigm Sas | Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai |
| PL3229843T3 (pl) * | 2014-11-25 | 2020-06-29 | Curadigm Sas | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) * | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EA201792560A1 (ru) | 2015-05-28 | 2018-06-29 | Нанобиотикс | Наночастицы для применения в качестве терапевтической вакцины |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| MX2019002474A (es) | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CN106420665B (zh) * | 2016-10-28 | 2019-04-16 | 浙江省林业科学研究院 | 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法 |
| WO2019070850A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| US20220401374A1 (en) * | 2019-09-13 | 2022-12-22 | Purdue Research Foundation | Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules |
| EP4051241A4 (en) * | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| MX2022005715A (es) * | 2019-11-11 | 2022-09-19 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
| WO2021158937A1 (en) * | 2020-02-05 | 2021-08-12 | The Johns Hopkins University | Bortezomib-loaded nanoparticles |
| EP4375659B1 (en) * | 2022-11-28 | 2025-03-26 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| WO2000006152A1 (en) * | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| SG178873A1 (en) * | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| HRP20160609T1 (hr) * | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| WO2012092712A1 (zh) * | 2011-01-07 | 2012-07-12 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂 |
| CN102078306A (zh) * | 2011-01-11 | 2011-06-01 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂 |
-
2013
- 2013-03-11 US US13/794,705 patent/US20140186447A1/en not_active Abandoned
- 2013-12-19 KR KR1020157020337A patent/KR20150100903A/ko not_active Withdrawn
- 2013-12-19 SG SG11201505111TA patent/SG11201505111TA/en unknown
- 2013-12-19 WO PCT/US2013/076630 patent/WO2014105644A1/en not_active Ceased
- 2013-12-19 MX MX2015008361A patent/MX2015008361A/es unknown
- 2013-12-19 NZ NZ630912A patent/NZ630912A/en unknown
- 2013-12-19 HK HK16104504.3A patent/HK1216611A1/zh unknown
- 2013-12-19 CN CN201380073926.7A patent/CN105007912A/zh active Pending
- 2013-12-19 RU RU2015131141A patent/RU2663687C2/ru active
- 2013-12-19 JP JP2015550675A patent/JP2016504362A/ja active Pending
- 2013-12-19 BR BR112015015319A patent/BR112015015319A2/pt not_active Application Discontinuation
- 2013-12-19 CA CA2896288A patent/CA2896288A1/en not_active Abandoned
- 2013-12-19 AU AU2013370955A patent/AU2013370955B2/en active Active
- 2013-12-19 EP EP13868481.6A patent/EP2938340A4/en not_active Withdrawn
-
2015
- 2015-06-23 IL IL239593A patent/IL239593A0/en unknown
- 2015-06-26 NI NI201500090A patent/NI201500090A/es unknown
- 2015-06-26 PH PH12015501486A patent/PH12015501486B1/en unknown
- 2015-07-02 ZA ZA2015/04762A patent/ZA201504762B/en unknown
- 2015-07-22 CR CR20150386A patent/CR20150386A/es unknown
-
2018
- 2018-02-23 JP JP2018030637A patent/JP2018087241A/ja active Pending
- 2018-10-25 US US16/170,522 patent/US20190192477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2896288A1 (en) | 2014-07-03 |
| SG11201505111TA (en) | 2015-07-30 |
| RU2015131141A (ru) | 2017-02-03 |
| HK1216611A1 (zh) | 2016-11-25 |
| EP2938340A4 (en) | 2016-08-03 |
| KR20150100903A (ko) | 2015-09-02 |
| JP2016504362A (ja) | 2016-02-12 |
| EP2938340A1 (en) | 2015-11-04 |
| AU2013370955A1 (en) | 2015-07-16 |
| CN105007912A (zh) | 2015-10-28 |
| WO2014105644A1 (en) | 2014-07-03 |
| IL239593A0 (en) | 2015-08-31 |
| US20140186447A1 (en) | 2014-07-03 |
| AU2013370955B2 (en) | 2018-12-06 |
| PH12015501486A1 (en) | 2015-09-21 |
| NZ630912A (en) | 2017-05-26 |
| BR112015015319A2 (pt) | 2017-07-11 |
| JP2018087241A (ja) | 2018-06-07 |
| MX2015008361A (es) | 2016-03-11 |
| PH12015501486B1 (en) | 2020-12-16 |
| US20190192477A1 (en) | 2019-06-27 |
| RU2663687C2 (ru) | 2018-08-08 |
| ZA201504762B (en) | 2016-10-26 |
| CR20150386A (es) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201500090A (es) | Composiciones de nanopartículas de albúmina y paclitaxel | |
| CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
| CY2018022I2 (el) | Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων | |
| PE20151023A1 (es) | Triazolopirazinas | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| MX2022003458A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
| ECSP14013284A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
| GT201500063A (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| EP2804599A4 (en) | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| UY35055A (es) | Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| BR112014015753A2 (pt) | derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção | |
| UY34776A (es) | Formulaciones de bromocriptina | |
| BR112017000022A2 (pt) | nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas | |
| UY34829A (es) | Nueva dosificación y formulación |